Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Michael W. Fried, M.D., Mitchell L. Shiffman, M.D., K. Rajender Reddy, M.D., Coleman Smith, M.D., George Marinos, M.D., Fernando L. Gonçales, Jr., M.D., Dieter Häussinger, M.D., Moises Diago, M.D., Giampiero Carosi, M.D., Daniel Dhumeaux, M.D., Antonio Craxi, M.D., Amy Lin, M.S., Joseph Hoffman, M.D., and Jian Yu, M.D., Ph.D.
Background Treatment with peginterferon alfa-2a alone producessignificantly higher sustained virologic responses than treatmentwith interferon alfa-2a alone in patients with chronic hepatitisC virus (HCV) infection. We compared the efficacy and safetyof peginterferon alfa-2a plus ribavirin, interferon alfa-2bplus ribavirin, and peginterferon alfa-2a alone in the initialtreatment of chronic hepatitis C.
Methods A total of 1121 patients were randomly assigned to treatmentand received at least one dose of study medication, consistingof 180 µg of peginterferon alfa-2a once weekly plus dailyribavirin (1000 or 1200 mg, depending on body weight), weeklypeginterferon alfa-2a plus daily placebo, or 3 million unitsof interferon alfa-2b thrice weekly plus daily ribavirin for48 weeks.
Results A significantly higher proportion of patients who receivedpeginterferon alfa-2a plus ribavirin had a sustained virologicresponse (defined as the absence of detectable HCV RNA 24 weeksafter cessation of therapy) than of patients who received interferonalfa-2b plus ribavirin (56 percent vs. 44 percent, P<0.001)or peginterferon alfa-2a alone (56 percent vs. 29 percent, P<0.001).The proportions of patients with HCV genotype 1 who had sustainedvirologic responses were 46 percent, 36 percent, and 21 percent,respectively, for the three regimens. Among patients with HCVgenotype 1 and high base-line levels of HCV RNA, the proportionsof those with sustained virologic responses were 41 percent,33 percent, and 13 percent, respectively. The overall safety profiles of the three treatment regimens were similar;the incidenceof influenza-like symptoms and depression was lower in the groupsreceiving peginterferon alfa-2a than in the group receivinginterferon alfa-2b plus ribavirin.
From the University of North Carolina, Chapel Hill (M.W.F.); the Medical College of Virginia, Richmond (M.L.S.); the University of Miami, Miami (K.R.R.); Minnesota Clinical Research Center, St. Paul (C.S.); Prince of Wales Hospital, Randwick, N.S.W., Australia (G.M.); Cidade Universitária Zeferino Vaz, Campinas, Brazil (F.L.G.); Heinrich-Heine-Universität, Düsseldorf, Germany (D.H.); General Universitario, Valencia, Spain (M.D.); Università degli Studi Brescia, Brescia, Italy (G.C.); Hôpital Henri Mondor, Creteil, France (D.D.); University of Palermo, Palermo, Italy (A.C.); and Hoffmann–LaRoche, Nutley, N.J. (J.H., A.L., J.Y.).
Address reprint requests to Dr. Fried at the University of North Carolina, CB# 7080, Rm. 708, Burnett Womack Bldg., Chapel Hill, NC 27599.
Patel, J.H., Cobbold, J.F.L., Thomas, H.C., Taylor-Robinson, S.D.
(2010). Hepatitis C and hepatic steatosis. QJM
0: hcp192v1-hcp192
[Abstract][Full Text]
Kieffer, T. L., Kwong, A. D., Picchio, G. R.
(2010). Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother
65: 202-212
[Abstract][Full Text]
Hopkins, S., Scorneaux, B., Huang, Z., Murray, M. G., Wring, S., Smitley, C., Harris, R., Erdmann, F., Fischer, G., Ribeill, Y.
(2010). SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro. Antimicrob. Agents Chemother.
54: 660-672
[Abstract][Full Text]
O'Leary, J. G., Davis, G. L.
(2010). Review: Hepatitis C virus replication and potential targets for direct-acting agents. Therapeutic Advances in Gastroenterology
3: 43-53
[Abstract]
Martin, C. K., Hostetter, J. E., Hagan, J. J.
(2010). New Opportunities for the Management and Therapy of Hepatitis C in Correctional Settings. AJPH
100: 13-17
[Abstract][Full Text]
Mangia, A., Andriulli, A.
(2010). Tailoring the length of antiviral treatment for hepatitis C. Gut
59: 1-5
[Full Text]
Vidal-Castineira, J. R., Lopez-Vazquez, A., Diaz-Pena, R., Alonso-Arias, R., Martinez-Borra, J., Perez, R., Fernandez-Suarez, J., Melon, S., Prieto, J., Rodrigo, L., Lopez-Larrea, C.
(2010). Effect of Killer Immunoglobulin-Like Receptors in the Response to Combined Treatment in Patients with Chronic Hepatitis C Virus Infection. J. Virol.
84: 475-481
[Abstract][Full Text]
Cheng, Y., Tsou, L. K., Cai, J., Aya, T., Dutschman, G. E., Gullen, E. A., Grill, S. P., Chen, A. P.-C., Lindenbach, B. D., Hamilton, A. D., Cheng, Y.-c.
(2010). A Novel Class of meso-Tetrakis-Porphyrin Derivatives Exhibits Potent Activities against Hepatitis C Virus Genotype 1b Replicons In Vitro. Antimicrob. Agents Chemother.
54: 197-206
[Abstract][Full Text]
Woltman, A M, Boonstra, A, Janssen, H L A
(2010). Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels?. Gut
59: 115-125
[Full Text]
Fraenkel, L., Chodkowski, D., Lim, J., Garcia-Tsao, G.
(2010). Patients' Preferences for Treatment of Hepatitis C. Med Decis Making
30: 45-57
[Abstract]
Brixner, D. I., Ye, X., Chu, T.-C., Blumentals, W. A., Hassanein, T. I.
(2009). Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin. Am J Health Syst Pharm
66: 2171-2178
[Abstract][Full Text]
Jiang, J., Luo, G.
(2009). Apolipoprotein E but Not B Is Required for the Formation of Infectious Hepatitis C Virus Particles. J. Virol.
83: 12680-12691
[Abstract][Full Text]
Chan, A. H., Partovi, N., Ensom, M. H.
(2009). The Utility of Therapeutic Drug Monitoring for Ribavirin in Patients with Chronic Hepatitis C--A Critical Review. The Annals of Pharmacotherapy
43: 2044-2063
[Abstract][Full Text]
Humphreys, I., Fleming, V., Fabris, P., Parker, J., Schulenberg, B., Brown, A., Demetriou, C., Gaudieri, S., Pfafferott, K., Lucas, M., Collier, J., Huang, K.-H. G., Pybus, O. G., Klenerman, P., Barnes, E.
(2009). Full-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute Infection. J. Virol.
83: 11456-11466
[Abstract][Full Text]
Backus, L. I, Gavrilov, S., Loomis, T. P, Halloran, J. P, Phillips, B. R, Belperio, P. S, Mole, L. A
(2009). Clinical Case Registries: Simultaneous Local and National Disease Registries for Population Quality Management. J Am Med Inform Assoc
16: 775-783
[Abstract][Full Text]
Hauser, P., Morasco, B. J., Linke, A., Bjornson, D., Ruimy, S., Matthews, A., Rifai, A., Indest, D. W., Loftis, J. M.
(2009). Antiviral Completion Rates and Sustained Viral Response in Hepatitis C Patients With and Without Preexisting Major Depressive Disorder. Psychosomatics
50: 500-505
[Abstract][Full Text]
Treloar, C., Rhodes, T.
(2009). The Lived Experience of Hepatitis C and its Treatment Among Injecting Drug Users: Qualitative Synthesis. Qual Health Res
19: 1321-1334
[Abstract]
Pisani, G., Cristiano, K., Marino, F., Luciani, F., Bisso, G. M., Mele, C., Adriani, D., Gentili, G., Wirz, M.
(2009). Quantification of Hepatitis C Virus (HCV) RNA in a Multicenter Study: Implications for Management of HCV Genotype 1-Infected Patients. J. Clin. Microbiol.
47: 2931-2936
[Abstract][Full Text]
Navaneethan, U., Kemmer, N., Neff, G. W.
(2009). Review: Predicting the probable outcome of treatment in HCV patients. Therapeutic Advances in Gastroenterology
2: 287-302
[Abstract]
Sarasin-Filipowicz, M., Wang, X., Yan, M., Duong, F. H. T., Poli, V., Hilton, D. J., Zhang, D.-E., Heim, M. H.
(2009). Alpha Interferon Induces Long-Lasting Refractoriness of JAK-STAT Signaling in the Mouse Liver through Induction of USP18/UBP43. Mol. Cell. Biol.
29: 4841-4851
[Abstract][Full Text]
Gordon, C. E., Uhlig, K., Lau, J., Schmid, C. H., Levey, A. S., Wong, J. B.
(2009). Interferon for Hepatitis C Virus in Hemodialysis--an Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response. CJASN
4: 1449-1458
[Abstract][Full Text]
Weatherford, T., Chavez, D., Brasky, K. M., Lemon, S. M., Martin, A., Lanford, R. E.
(2009). Lack of Adaptation of Chimeric GB Virus B/Hepatitis C Virus in the Marmoset Model: Possible Effects of Bottleneck. J. Virol.
83: 8062-8075
[Abstract][Full Text]
Takeshita, M., Ishida, Y.-i., Akamatsu, E., Ohmori, Y., Sudoh, M., Uto, H., Tsubouchi, H., Kataoka, H.
(2009). Proanthocyanidin from Blueberry Leaves Suppresses Expression of Subgenomic Hepatitis C Virus RNA. J. Biol. Chem.
284: 21165-21176
[Abstract][Full Text]
McHutchison, J. G., Lawitz, E. J., Shiffman, M. L., Muir, A. J., Galler, G. W., McCone, J., Nyberg, L. M., Lee, W. M., Ghalib, R. H., Schiff, E. R., Galati, J. S., Bacon, B. R., Davis, M. N., Mukhopadhyay, P., Koury, K., Noviello, S., Pedicone, L. D., Brass, C. A., Albrecht, J. K., Sulkowski, M. S., the IDEAL Study Team,
(2009). Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. NEJM
361: 580-593
[Abstract][Full Text]
Kiser, J. J.
(2009). Trends in the Treatment of Chronic Hepatitis C Virus Infection. Journal of Pharmacy Practice
22: 405-418
[Abstract]
Scarsi, K. K., Darin, K. M.
(2009). Chronic Hepatitis B Infection: Principles of Therapy. Journal of Pharmacy Practice
22: 359-387
[Abstract]
Rotman, Y., Liang, T. J.
(2009). Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes. J. Virol.
83: 7366-7374
[Full Text]
Chang, D.-Y., Shin, E.-C.
(2009). Immune-based therapy for chronic hepatitis C. J. Leukoc. Biol.
86: 33-39
[Abstract][Full Text]
Pawlotsky, J.-M.
(2009). Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therapeutic Advances in Gastroenterology
2: 205-219
[Abstract]
Dahari, H., Sainz, B. Jr., Perelson, A. S., Uprichard, S. L.
(2009). Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon. J. Virol.
83: 6383-6390
[Abstract][Full Text]
Nash, K. L, Bentley, I., Hirschfield, G. M
(2009). Managing hepatitis C virus infection. BMJ
338: b2366-b2366
[Full Text]
Wilck, M. B., Hamel, M. B., Baden, L. R.
(2009). Management of Incidental Hepatitis C Virus Infection -- Polling Results. NEJM
360: e30-e30
[Full Text]
Shi, S. T., Herlihy, K. J., Graham, J. P., Nonomiya, J., Rahavendran, S. V., Skor, H., Irvine, R., Binford, S., Tatlock, J., Li, H., Gonzalez, J., Linton, A., Patick, A. K., Lewis, C.
(2009). Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob. Agents Chemother.
53: 2544-2552
[Abstract][Full Text]
Qiu, P., Sanfiorenzo, V., Curry, S., Guo, Z., Liu, S., Skelton, A., Xia, E., Cullen, C., Ralston, R., Greene, J., Tong, X.
(2009). Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res
37: e74-e74
[Abstract][Full Text]
Asselah, T, Bieche, I, Sabbagh, A, Bedossa, P, Moreau, R, Valla, D, Vidaud, M, Marcellin, P
(2009). Gene expression and hepatitis C virus infection. Gut
58: 846-858
[Abstract][Full Text]
Li, L., Koo, S. H., Limenta, L. M. G., Han, L., Hashim, K. B., Quek, H. H., Lee, E. J. D.
(2009). Effect of Dietary Purines on the Pharmacokinetics of Orally Administered Ribavirin. J Clin Pharmacol
49: 661-667
[Abstract][Full Text]
Burlone, M. E., Budkowska, A.
(2009). Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J. Gen. Virol.
90: 1055-1070
[Abstract][Full Text]
McCown, M. F., Rajyaguru, S., Kular, S., Cammack, N., Najera, I.
(2009). GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796. Antimicrob. Agents Chemother.
53: 2129-2132
[Abstract][Full Text]
McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., Muir, A. J., the PROVE1 Study Team,
(2009). Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection. NEJM
360: 1827-1838
[Abstract][Full Text]
Hezode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourliere, M., Gharakhanian, S., Bengtsson, L., McNair, L., George, S., Kieffer, T., Kwong, A., Kauffman, R. S., Alam, J., Pawlotsky, J.-M., Zeuzem, S., the PROVE2 Study Team,
(2009). Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. NEJM
360: 1839-1850
[Abstract][Full Text]
Hoofnagle, J. H.
(2009). A Step Forward in Therapy for Hepatitis C. NEJM
360: 1899-1901
[Full Text]
(2009). Management of Incidental Hepatitis C Virus Infection. NEJM
360: 1902-1906
[Full Text]
Jensen, D. M., Marcellin, P., Freilich, B., Andreone, P., Di Bisceglie, A., Brandao-Mello, C. E., Reddy, K. R., Craxi, A., Martin, A. O., Teuber, G., Messinger, D., Thommes, J. A., Tietz, A.
(2009). Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-{alpha}2b: A Randomized Trial. ANN INTERN MED
150: 528-540
[Abstract][Full Text]
Poordad, F., Landaverde, C.
(2009). Review: Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients. Therapeutic Advances in Gastroenterology
2: 91-97
[Abstract]
Jeffe, F., Stegmann, K. A., Broelsch, F., Manns, M. P., Cornberg, M., Wedemeyer, H.
(2009). Adenosine and IFN-{alpha} synergistically increase IFN-{gamma} production of human NK cells. J. Leukoc. Biol.
85: 452-461
[Abstract][Full Text]
Yee, L. J., Im, K., Wahed, A. S., Bugawan, T., Li, J., Rhodes, S. L., Erlich, H., Rosen, H. R., Liang, T. J., Yang, H., for the Virahep-C Study,
(2009). Polymorphism in the Human Major Histocompatibility Complex and Early Viral Decline during Treatment of Chronic Hepatitis C. Antimicrob. Agents Chemother.
53: 615-621
[Abstract][Full Text]
Flint, M., Mullen, S., Deatly, A. M., Chen, W., Miller, L. Z., Ralston, R., Broom, C., Emini, E. A., Howe, A. Y. M.
(2009). Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034). Antimicrob. Agents Chemother.
53: 401-411
[Abstract][Full Text]
Matsuura, K., Tanaka, Y., Hasegawa, I., Ohno, T., Tokuda, H., Kurbanov, F., Sugauchi, F., Nojiri, S., Joh, T., Mizokami, M.
(2009). Abbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients. J. Clin. Microbiol.
47: 385-389
[Abstract][Full Text]
Cohen, S. M., Kwasny, M. J, Ahn, J.
(2009). Use of Specialty Care Versus Standard Retail Pharmacies for Treatment of Hepatitis C. The Annals of Pharmacotherapy
43: 202-209
[Abstract][Full Text]
Rodriguez-Torres, M., Jeffers, L. J., Sheikh, M. Y., Rossaro, L., Ankoma-Sey, V., Hamzeh, F. M., Martin, P., the Latino Study Group,
(2009). Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C. NEJM
360: 257-267
[Abstract][Full Text]
Pybus, O. G., Barnes, E., Taggart, R., Lemey, P., Markov, P. V., Rasachak, B., Syhavong, B., Phetsouvanah, R., Sheridan, I., Humphreys, I. S., Lu, L., Newton, P. N., Klenerman, P.
(2009). Genetic History of Hepatitis C Virus in East Asia. J. Virol.
83: 1071-1082
[Abstract][Full Text]
Jensen, D. M.
(2009). Individualizing HCV treatment with peginterferon and ribavirin: what needs to be done?. Therapeutic Advances in Gastroenterology
2: 5-10
Di Bisceglie, A. M., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Everhart, J. E., Wright, E. C., Lee, W. M., Lok, A. S., Bonkovsky, H. L., Morgan, T. R., Ghany, M. G., Morishima, C., Snow, K. K., Dienstag, J. L., the HALT-C Trial Investigators,
(2008). Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. NEJM
359: 2429-2441
[Abstract][Full Text]
Mira, J. A., Lopez-Cortes, L. F., Barreiro, P., Tural, C., Torres-Tortosa, M., de los Santos Gil, I., Martin-Rico, P., Rios-Villegas, M. J., Hernandez-Burruezo, J. J., Merino, D., Lopez-Ruz, M. A., Rivero, A., Munoz, L., Gonzalez-Serrano, M., Collado, A., Macias, J., Viciana, P., Soriano, V., Pineda, J. A.
(2008). Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother
62: 1365-1373
[Abstract][Full Text]
Morello, J., Rodriguez-Novoa, S., Jimenez-Nacher, I., Soriano, V.
(2008). Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother
62: 1174-1180
[Abstract][Full Text]
Timpe, J M, McKeating, J A
(2008). Hepatitis C virus entry: possible targets for therapy. Gut
57: 1728-1737
[Full Text]
Vermehren, J., Kau, A., Gartner, B. C., Gobel, R., Zeuzem, S., Sarrazin, C.
(2008). Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and Quantification. J. Clin. Microbiol.
46: 3880-3891
[Abstract][Full Text]
Seiwert, S. D., Andrews, S. W., Jiang, Y., Serebryany, V., Tan, H., Kossen, K., Rajagopalan, P. T. R., Misialek, S., Stevens, S. K., Stoycheva, A., Hong, J., Lim, S. R., Qin, X., Rieger, R., Condroski, K. R., Zhang, H., Do, M. G., Lemieux, C., Hingorani, G. P., Hartley, D. P., Josey, J. A., Pan, L., Beigelman, L., Blatt, L. M.
(2008). Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother.
52: 4432-4441
[Abstract][Full Text]
Ali, S., Leveque, V., Le Pogam, S., Ma, H., Philipp, F., Inocencio, N., Smith, M., Alker, A., Kang, H., Najera, I., Klumpp, K., Symons, J., Cammack, N., Jiang, W.-R.
(2008). Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479. Antimicrob. Agents Chemother.
52: 4356-4369
[Abstract][Full Text]
Nyanguile, O., Pauwels, F., Van den Broeck, W., Boutton, C. W., Quirynen, L., Ivens, T., van der Helm, L., Vandercruyssen, G., Mostmans, W., Delouvroy, F., Dehertogh, P., Cummings, M. D., Bonfanti, J.-F., Simmen, K. A., Raboisson, P.
(2008). 1,5-Benzodiazepines, a Novel Class of Hepatitis C Virus Polymerase Nonnucleoside Inhibitors. Antimicrob. Agents Chemother.
52: 4420-4431
[Abstract][Full Text]
Wiegand, J., Deterding, K., Cornberg, M., Wedemeyer, H.
(2008). Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon {alpha}. J Antimicrob Chemother
62: 860-865
[Abstract][Full Text]
Gao, D.-Y., Zhang, X.-X., Hou, G., Jin, G.-D., Deng, Q., Kong, X.-F., Zhang, D.-H., Ling, Y., Yu, D.-M., Gong, Q.-M., Zhan, Q., Yao, B.-L., Lu, Z.-M.
(2008). Assessment of Specific Antibodies to F Protein in Serum Samples from Chinese Hepatitis C Patients Treated with Interferon plus Ribavarin. J. Clin. Microbiol.
46: 3746-3751
[Abstract][Full Text]
Badr, G., Bedard, N., Abdel-Hakeem, M. S., Trautmann, L., Willems, B., Villeneuve, J.-P., Haddad, E. K., Sekaly, R. P., Bruneau, J., Shoukry, N. H.
(2008). Early Interferon Therapy for Hepatitis C Virus Infection Rescues Polyfunctional, Long-Lived CD8+ Memory T Cells. J. Virol.
82: 10017-10031
[Abstract][Full Text]
Herlihy, K. J., Graham, J. P., Kumpf, R., Patick, A. K., Duggal, R., Shi, S. T.
(2008). Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors. Antimicrob. Agents Chemother.
52: 3523-3531
[Abstract][Full Text]
Black, M., Thomas, R.
(2008). Antiviral Treatment for Hepatitis C Cirrhosis: Is the Effort Justified?. ANN INTERN MED
149: 427-428
[Full Text]
Hraber, P., Kuiken, C., Waugh, M., Geer, S., Bruno, W. J., Leitner, T.
(2008). Classification of hepatitis C virus and human immunodeficiency virus-1 sequences with the branching index. J. Gen. Virol.
89: 2098-2107
[Abstract][Full Text]
Kimura, T., Imamura, M., Hiraga, N., Hatakeyama, T., Miki, D., Noguchi, C., Mori, N., Tsuge, M., Takahashi, S., Fujimoto, Y., Iwao, E., Ochi, H., Abe, H., Maekawa, T., Arataki, K., Tateno, C., Yoshizato, K., Wakita, T., Okamoto, T., Matsuura, Y., Chayama, K.
(2008). Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. J. Gen. Virol.
89: 2108-2113
[Abstract][Full Text]
Lin, Y., Kwon, T., Polo, J., Zhu, Y.-F., Coates, S., Crawford, K., Dong, C., Wininger, M., Hall, J., Selby, M., Coit, D., Medina-Selby, A., McCoin, C., Ng, P., Drane, D., Chien, D., Han, J., Vajdy, M., Houghton, M.
(2008). Induction of Broad CD4+ and CD8+ T-Cell Responses and Cross- Neutralizing Antibodies against Hepatitis C Virus by Vaccination with Th1-Adjuvanted Polypeptides Followed by Defective Alphaviral Particles Expressing Envelope Glycoproteins gpE1 and gpE2 and Nonstructural Proteins 3, 4, and 5 . J. Virol.
82: 7492-7503
[Abstract][Full Text]
Mimura, I., Ishibashi, Y., Tateishi, R., Kaname, S., Fujita, T.
(2008). Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C. NDT Plus
1: 233-235
[Abstract][Full Text]
Harmatz, P., Jonas, M. M., Kwiatkowski, J. L., Wright, E. C., Fischer, R., Vichinsky, E., Giardina, P. J., Neufeld, E. J., Porter, J., Olivieri, N., for the Thalassemia Clinical Research Network,
(2008). Safety and efficacy of pegylated interferon {alpha}-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. haematol
93: 1247-1251
[Abstract][Full Text]
Yamane, A., Nakamura, T., Suzuki, H., Ito, M., Ohnishi, Y., Ikeda, Y., Miyakawa, Y.
(2008). Interferon-{alpha}2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood
112: 542-550
[Abstract][Full Text]
Le Pogam, S., Seshaadri, A., Kosaka, A., Chiu, S., Kang, H., Hu, S., Rajyaguru, S., Symons, J., Cammack, N., Najera, I.
(2008). Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother
61: 1205-1216
[Abstract][Full Text]
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., Heim, M. H.
(2008). Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA
105: 7034-7039
[Abstract][Full Text]
Dieperink, E., Leskela, J., Dieperink, M. E., Evans, B., Thuras, P., Ho, S. B.
(2008). The Effect of Pegylated Interferon-{alpha}2b and Ribavirin on Posttraumatic Stress Disorder Symptoms. Psychosomatics
49: 225-229
[Abstract][Full Text]
McCown, M. F., Rajyaguru, S., Le Pogam, S., Ali, S., Jiang, W.-R., Kang, H., Symons, J., Cammack, N., Najera, I.
(2008). The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors. Antimicrob. Agents Chemother.
52: 1604-1612
[Abstract][Full Text]
Rousseau, C. M., Ioannou, G. N., Todd-Stenberg, J. A., Sloan, K. L., Larson, M. F., Forsberg, C. W., Dominitz, J. A.
(2008). Racial Differences in the Evaluation and Treatment of Hepatitis C Among Veterans: A Retrospective Cohort Study. AJPH
98: 846-852
[Abstract][Full Text]
Persico, M, Capasso, M, Russo, R, Persico, E, Croce, L, Tiribelli, C, Iolascon, A
(2008). Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut
57: 507-515
[Abstract][Full Text]
Asselah, T, Bieche, I, Narguet, S, Sabbagh, A, Laurendeau, I, Ripault, M-P, Boyer, N, Martinot-Peignoux, M, Valla, D, Vidaud, M, Marcellin, P
(2008). Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut
57: 516-524
[Abstract][Full Text]
Kraus, M R, Schafer, A, Schottker, K, Keicher, C, Weissbrich, B, Hofbauer, I, Scheurlen, M
(2008). Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut
57: 531-536
[Abstract][Full Text]
Cross, T J S, Antoniades, C G, Harrison, P M
(2008). Current and future management of chronic hepatitis C infection. Postgrad. Med. J.
84: 172-176
[Abstract][Full Text]
Golden-Mason, L., Klarquist, J., Wahed, A. S., Rosen, H. R.
(2008). Cutting Edge: Programmed Death-1 Expression Is Increased on Immunocytes in Chronic Hepatitis C Virus and Predicts Failure of Response to Antiviral Therapy: Race-Dependent Differences. J. Immunol.
180: 3637-3641
[Abstract][Full Text]
van Leusen, R., Adang, R. P. R., de Vries, R. A., Cnossen, T. T., Konings, C. J. A. M., Schalm, S. W., Tan, A. C. I. T. L.
(2008). Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant
23: 721-725
[Abstract][Full Text]
Shi, S. T., Herlihy, K. J., Graham, J. P., Fuhrman, S. A., Doan, C., Parge, H., Hickey, M., Gao, J., Yu, X., Chau, F., Gonzalez, J., Li, H., Lewis, C., Patick, A. K., Duggal, R.
(2008). In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob. Agents Chemother.
52: 675-683
[Abstract][Full Text]
Klumpp, K., Kalayanov, G., Ma, H., Le Pogam, S., Leveque, V., Jiang, W.-R., Inocencio, N., De Witte, A., Rajyaguru, S., Tai, E., Chanda, S., Irwin, M. R., Sund, C., Winqist, A., Maltseva, T., Eriksson, S., Usova, E., Smith, M., Alker, A., Najera, I., Cammack, N., Martin, J. A., Johansson, N. G., Smith, D. B.
(2008). 2'-Deoxy-4'-azido Nucleoside Analogs Are Highly Potent Inhibitors of Hepatitis C Virus Replication Despite the Lack of 2'-{alpha}-Hydroxyl Groups. J. Biol. Chem.
283: 2167-2175
[Abstract][Full Text]
Supekova, L., Supek, F., Lee, J., Chen, S., Gray, N., Pezacki, J. P., Schlapbach, A., Schultz, P. G.
(2008). Identification of Human Kinases Involved in Hepatitis C Virus Replication by Small Interference RNA Library Screening. J. Biol. Chem.
283: 29-36
[Abstract][Full Text]
Zhou, Y., Bartels, D. J., Hanzelka, B. L., Muh, U., Wei, Y., Chu, H.-M., Tigges, A. M., Brennan, D. L., Rao, B. G., Swenson, L., Kwong, A. D., Lin, C.
(2008). Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease. Antimicrob. Agents Chemother.
52: 110-120
[Abstract][Full Text]
Tasaka, M., Sakamoto, N., Itakura, Y., Nakagawa, M., Itsui, Y., Sekine-Osajima, Y., Nishimura-Sakurai, Y., Chen, C.-H., Yoneyama, M., Fujita, T., Wakita, T., Maekawa, S., Enomoto, N., Watanabe, M.
(2007). Hepatitis C virus non-structural proteins responsible for suppression of the RIG-I/Cardif-induced interferon response. J. Gen. Virol.
88: 3323-3333
[Abstract][Full Text]
Murray, K. F., Rodrigue, J. R., Gonzalez-Peralta, R. P., Shepherd, J., Barton, B. A., Robuck, P. R., Schwarz, K. B., for the PEDS-C Clinical Research Network,
(2007). Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. Clin Trials
4: 661-673
[Abstract]
Pineda, J. A., Mira, J. A., Gil, I. d. l. S., Valera-Bestard, B., Rivero, A., Merino, D., Giron-Gonzalez, J. A., Rios-Villegas, M. J., Gonzalez-Serrano, M., Collado, A., Garcia-Garcia, J. A., Carrillo-Gomez, R., Lopez-Cortes, L. F., Gomez-Mateos, J.
(2007). Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother
60: 1347-1354
[Abstract][Full Text]
Omata, M., Yoshida, H., Toyota, J., Tomita, E., Nishiguchi, S., Hayashi, N., Iino, S., Makino, I., Okita, K., Toda, G., Tanikawa, K., Kumada, H., for the Japanese C-Viral Hepatitis Network,
(2007). A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut
56: 1747-1753
[Abstract][Full Text]
Previous
